Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Already beavering away at building a US commercial operation, MorphoSys $MOR is now bearing down on Novartis and Gilead with a potential CAR-T killer soon to be put into the hands of US regulators.
The German biotech says its final cut of the data on their CD19-targeting antibody tafasitamab — or MOR208 — combined with lenalidomide crossed the finish line in a group of patients suffering from treatment-resistant DLBCL, a common form of non-Hodgkin lymphoma.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 73,300+ biopharma pros reading Endpoints daily — and it's free.